CEO Interview: Ulcerative Colitis Trial Shows Abivax's HIV Candidate Has Broader Potential

 
• By Sten Stovall

Abivax Phase IIa data for its lead asset showed impressive results in ulcerative colitis. The biotech's CEO tells Scrip trials in Crohn's disease and rheumatoid arthritis will now follow.

Gastrointestinal tract
Abivax Says Good Phase II Data In UC Transforms Pipeline Prospects • Source: Shutterstock

More from Strategy

More from Business